Announcements Trials
Browse Landscape

Phase

Phase 1/2 4Phase 1 3Phase 2 2

Status

Terminated 2Completed 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 2Dermatologic 1

Conditions

Recurrence 1Neuroblastoma 1Neoplasm Metastasis 1Melanoma 1Medulloblastoma 1Brain Neoplasms 1

Interventions

Cyclophosphamide 416Radiotherapy 276fludarabine 238Gemcitabine 211Cisplatin 203Nivolumab 184pembrolizumab 183Paclitaxel 176Carboplatin 168Magnetic Resonance Spectroscopy 166fludarabine phosphate 156Irinotecan 135Bevacizumab 133Cytarabine 128Specimen Handling 124Capecitabine 124Temozolomide 123Radiosurgery 118Docetaxel 116Biopsy 116Ipilimumab 113Dexamethasone 113Radiation 111Oxaliplatin 110Fluorouracil 110Rituximab 108Etoposide 108Filgrastim 99Lenalidomide 98Everolimus 96

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × OTHER × TPI-287 × Clear all
NCT00867568 2024-08-06

TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma

Milton S. Hershey Medical Center

Phase 1 Completed
18 enrolled 12 charts
CNS

Medulloblastoma, Neuroblastoma, Recurrence

NCT02187822 2021-02-04

Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Terminated
15 enrolled
CNS

Brain Neoplasms, Neoplasm Metastasis

NCT01067066 2017-07-21

A Phase I Study of TPI 287 - Temozolomide Combination in Melanoma

M.D. Anderson Cancer Center

Phase 1 Terminated
21 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡